Journal of Clinical Oncology
Articles in this Issue
Proteomic evaluation of HER-2 expression and activation in tumors that are RNA overexpressed, but not DNA amplified.
e15093 Background: HER2 evaluation with IHC and FISH has limitations in terms of prediction for response to anti-HER2 therapies. With a growing number of...
DetermaIO Kit: Decentralizing classification of the tumor microenvironment.
e14633 Background: The tumor microenvironment (TME) is critical in modulating cancer progression and therapeutic response, especially for immune checkpoin...
Tocilizumab prophylaxis for outpatient administration of teclistamab in relapsed/refractory multiple myeloma.
e19504 Background: Teclistamab is the first BCMA-directed bispecific antibody approved for the treatment of relapsed and refractory multiple myeloma (RRMM...
B-cell maturation antigen (BCMA) immunohistochemistry (IHC) staining in multiple myeloma (MM) patients with prior use of BCMA-based therapies.
e19540 Background: BCMA is a critical therapeutic target in multiple myeloma (MM), but resistance to BCMA-based therapies can occur due to altered BCMA ex...
A phase 1b study of SHR-2017, a RANKL/NGF targeted antibody, in patients (pts) with breast cancer bone metastasis.
12059 Background: Bone metastasis is a common site of metastasis in malignant tumors. For patients (pts) with bone metastasis, pain is the predominant sym...
Comparative diagnostic accuracy and tumor uptake of 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for detecting primary tumors, lymph node, and distant metastases in biliary tract cancers: A systematic review and meta-analysis.
e16235 Background: Biliary tract cancers (BTCs) are aggressive malignancies with poor prognosis, necessitating accurate diagnostic tools for confirming de...
Recognizing international medical graduates: Awards and committee membership in ASCO.
9008 Background: International Medical Graduates (IMGs) comprise one third of practicing oncologists and half of hematology-oncology fellows in the US. Th...
Predicting transposable element-derived neoantigens in ATRX-mutated sarcoma.
11529 Background: Epigenetic dysregulation is a key mechanism in cancer biology, driving both immune evasion and the generation of potentially druggable n...
Cost and resource utilisation for liquid biopsy vs tissue biopsy genotyping in advanced NSCLC: A micro-costing model.
1542 Background: For patients with advanced non-small cell lung cancer, tumour genotyping identifies actionable variants that inform targeted therapeutic...
A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
3029 Background: TROP-2 (trophoblast cell surface antigen 2) is commonly overexpressed in multiple solid tumors and associ...
Kidney disease related mortality: Trends and disparities among patients with multiple myeloma.
e19562 Background: Kidney disease is a common and severe comorbidity among patients with multiple myeloma, significantly impacting outcomes and mortality....
IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).
6515 Background: IME, a first-in-class, direct, and competitive inhibitor of telomerase activity, showed potential survival improvements and disease-modif...
Time from diagnosis to surgery for stage I non-small cell lung cancer among Native Hawaiians and other Pacific Islanders.
e13798 Background: Surgery is the standard of care for Stage I non-small cell lung cancer (NSCLC); however, treatment among racial minority groups, partic...
Trends in adverse events related to immunosuppressive treatments among patients with head and neck cancer and their impact on the burden of illness.
e23100 Background: Immunosuppressive cancer therapy has significantly transformed care, particularly for patients with head and neck cancers (HNC). Noneth...
Initial treatment and survival outcomes for early-stage NSCLC in Veterans: Insights from cancer cube data.
8047 Background: Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and remains the leading cause of cancer-related deaths in the Un...
Effect and mechanism of STF-31 combined with cisplatin in overcoming platinum resistance in ovarian cancer.
e17594 Background: Platinum-based chemotherapy is currently the first-line treatment for ovarian cancer patients. However, tumor cells gradually develop r...
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.
6048 Background: Recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) represents a marked unmet need. ROR2 is a cell-surface t...
Folate deficiency anemia in patients on PARP inhibition: Insights from a large single-center study.
e24105 Background: Poly ADP-ribose polymerase inhibitors (PARPi) constitute a novel therapeutic class for BRCA1/2 -associated mali...
First, do no harm: Evaluating clinical skills for patient safety in oncology fellows.
e21009 Background: This study aims to present the results and design of the Observational Standardized Clinical Examination (JCO 34, e18150, 2016) IOHM-US...
A mixed method integration of clinician distress typologies in those caring for seriously ill patients within the hospital setting.
e21000 Background: Hospital clinicians in the US care for almost 34 million patients each year; 40% of whom are seriously ill with one or more co-morbidit...
Evaluation of acute toxicity questionnaire adherence of nonmetastatic patients treated in an infusion center.
e23214 Background: During patient´s cancer treatment in infusion center, acute toxicity registration is a valuable tool to evaluate security and quality i...
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
3087 Background: Pre-clinical data have shown that mutations in isocitrate dehydrogenase (IDH) 1 and 2 can lead to a “BRCAness” phenotype by impairing hom...
Survival disparities in Asian Americans with epithelial ovarian cancer.
e17578 Background: Ovarian cancer represents a leading cancer-related cause of death among women in the United States, with approximately 20,890 new cases...
Survival outcomes in small cell lung cancer (SCLC) pre- and post-2018: A SEER-based analysis of the impact of immunotherapy advancements.
e13878 Background: Small cell lung cancer (SCLC) accounts for 15% of all lung cancers. It was historically treated with platinum-based chemotherapy. The 2...
Effect of incorporating symptom burden with mortality as a composite outcome on accuracy and bias in palliative care identification algorithms in oncology.
12016 Background: Machine learning (ML) algorithms are increasingly used to identify patients for early palliative care (PC) or advance care planning (ACP...